Publications by authors named "Chudi Nduaka"

Article Synopsis
  • Upadacitinib shows faster and more effective results in reducing atopic dermatitis severity compared to dupilumab over 24 weeks, based on the Eczema Area and Severity Index (EASI).
  • In a study, patients treated with upadacitinib achieved greater skin clearance rates of ≥75%, ≥90%, and 100% in all analyzed body regions earlier than those on dupilumab.
  • Patient feedback indicated that those on upadacitinib reported significantly better outcomes for symptoms in the head and neck area as soon as week 1.
View Article and Find Full Text PDF

Objective: To determine the rate of infection and all-cause mortality across tofacitinib phase II, phase III, and long-term extension (LTE) studies in patients with moderately to severely active rheumatoid arthritis (RA).

Methods: Pooled data from studies of tofacitinib in patients with RA were analyzed. In these studies, tofacitinib was administered as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs.

View Article and Find Full Text PDF